The contribution of HLA class II-restricted CD4 + T cell responses to HIV immune control is poorly defined. Here, we delineated previously uncharacterized peptide-DRB1 restrictions in functional assays and analyzed the host genetic effects of HLA-DRB1 alleles on HIV viremia in a large cohort of HIV controllers and progressors. We found distinct stratifications in the effect of HLA-DRB1 alleles on HIV viremia, with HLA-DRB1*15:02 significantly associated with low viremia and HLA-DRB1*03:01 significantly associated with high viremia. Notably, a subgroup of HLA-DRB1 variants linked with low viremia showed the ability to promiscuously present a larger breadth of peptides with lower functional avidity when compared to HLA-DRB1 variants linked with high viremia. Our data provide systematic evidence that HLA-DRB1 variant expression has a considerable impact on the control of HIV replication, an effect that seems to be mediated primarily by the protein specificity of CD4 + T cell responses to HIV Gag and Nef.
Control of viral infections is crucially dependent on CD4 + T cell responses [1] [2] [3] . CD4 + T cells provide help for the generation of highaffinity antibodies and the induction of memory in CD8 + T cells and B cells 4 and may also directly exert antiviral activity 2, 3, 5 . Yet the role of virus-specific CD4 + T cell responses in HIV infection is less clear 6 because HIV preferentially infects HIV-specific CD4 + T cells 7 . We have previously shown that the breadth and specificity of HIV-specific CD4 + T cell responses is significantly associated with low viremia 8 . However, little is known about the HLA class II restriction of these responses and how HLA class II alleles affect HIV control. The strongest known genetic association with HIV control is mediated by HLA class I alleles [9] [10] [11] such as HLA-B*57 (refs. 9-11), yet at least two studies have suggested that HLA class II alleles 12, 13 , particularly at the HLA-DRB1 locus, may also influence HIV control.
To define the role of DRB1-restricted HIV-specific CD4 + T cell responses on viral control, we tested 201 HIV-specific CD4 + T cell lines recognizing 67 peptide specificities from 42 HIV-infected individuals in functional HLA-DRB1 restriction assays. We observed a high level of promiscuity, a characteristic feature of antigen-specific CD4 + T cell recognition in which a single peptide can be presented in the context of multiple HLA class II variants expressed by different individuals 14 (Fig. 1a) . Notably, of all peptides tested across the HIV proteome ( Supplementary Table 1 ), 43% were restricted by two or more HLA-DR variants ( Supplementary Table 2 ). OLP-41 in Gag p24, which is the most frequently targeted peptide recognized by HIV-specific CD4 + T cells, showed the highest level of promiscuity, with 12 distinct HLA-DRB1 restrictions. We also evaluated the peptide-binding capacity 14 of five immunodominant peptides recognized by CD4 + T cells to 13 distinct HLA-DRB1 variants. These peptides showed comparable or even higher binding promiscuity ( Supplementary Table 3 ), thus confirming our restriction data. Furthermore, detailed analysis of OLP-41 revealed only limited variability in the minimal stimulatory epitopes presented by different HLA-DRB1 variants ( Supplementary Fig. 1 ), confirming that promiscuous HLA-DRB1 variants share largely overlapping epitope-binding registers 15, 16 . This high degree of peptide-binding promiscuity is probably mediated by the open conformation of HLA class II, which allows long peptides recognized by CD4 + T cells to extend beyond the HLA binding groove.
Despite the high degree of HLA-DRB1 binding promiscuity, we observed marked differences in the number of peptides restricted by each DRB1 variant ( Fig. 1b) . Variants such as DRB1*01:01 and DRB1*04:01 had the lowest contribution to the total number of peptide restrictions, with only three confirmed peptides, whereas DRB1*13:01, DRB1*13:02 and DRB1*13:03 restricted a total of 18, 11 and 8 HIV-specific peptides recognized by CD4 + T cells, respectively. Notably, expression of DRB1*13 variants, particularly of DRB1*13:03, has been associated with lower HIV viral load 12, 13 .
We next examined the relationship between HLA-DRB1 allele expression and viral load in a large cohort of 1,085 treatment-naive HIV-infected individuals of European ancestry from the combined Association of HLA-DRB1-restricted CD4 + T cell responses with HIV immune control Massachusetts General Hospital (MGH) and SCOPE (Observational Study of the Consequences of the Protease Inhibitor Era) cohorts. We categorized subjects into two groups, HIV controllers (<2,000 HIV RNA copies per ml) and HIV progressors (>10,000 HIV RNA copies per ml), and we then evaluated the effect of individual HLA-DRB1 allele expression on mean viral load in a logistic regression model. We used an odds ratio to analyze the strength of the associations, with <1 indicative of greater HIV control and >1 indicative of relatively poor HIV control. We used the well-defined HLA class I protective alleles HLA-B*57 and HLA-B*27 and the risk allele HLA-B*35Px (refs. 9,17) as covariates in this model to eliminate their confounding effects on HIV viremia. Notably, although we observed a wide range in the confidence intervals, there was a hierarchy of more protective to more hazardous HLA-DRB1 alleles (Fig. 2) . Specifically, subjects positive for HLA-DRB1*15:02 had the lowest odds ratio (0.22), and expression of this allele was significantly associated with control of HIV viremia (P = 0.003, q = 0.04). In contrast, HLA-DRB1*03:01 had the highest odds ratio (1.68) and was significantly associated with high viremia (P = 0.004, q = 0.04). We found distinct stratifications in the odds ratio associated with other HLA-DRB1 alleles, but we were underpowered to determine statistical differences in their association with HIV control after correction for multiple comparisons in this cohort. Whereas some of the HLA class II alleles associated with low viremia are relatively rare at the population level, we found no evidence of a 'rare allele' effect as suggested for HLA class I (ref. 18).
We previously described marked differences in the protein specificity of HIV-specific CD4 + T cell responses between HIV controllers and high-viremia progressors 8 . Therefore, we next investigated whether the HLA-DRB1 variants linked with either low or high viral load in our genetic study (MGH and SCOPE cohorts) restricted different HIV proteins in our initial functional screen. The cohorts used for the genetic and functional analyses were independent but did not differ in HLA-DRB1 frequencies ( Supplementary Fig. 2 and Supplementary Table 4 ). We grouped the HIV-specific CD4 + T cell responses on the basis of the upper quartile of HLA-DRB1 alleles linked with low viremia (HLA-DRB1*15:02, HLA-DRB1*10:01, HLA-DRB1*13:03, HLA-DRB1*09:01 and HLA-DRB1*13:02) and lower quartile of HLA-DRB1 alleles linked with high viremia (HLA-DRB1*03:01, HLA-DRB1*04:04, HLA-DRB1*01:01, HLA-DRB1*15:01 and HLA-DRB1*08:01). (HLA-DRB1*12:01 was not included owing to a lack of subjects expressing this allele in our functional cohort.) We assessed a total of 26 HIV-infected subjects (17 HIV controllers and 9 progressors) for the sum of promiscuous peptide-DRB1 restrictions per protein. Notably, we observed that HLA-DRB1 variants linked with low viremia showed a significantly greater number of peptide restrictions when compared to HLA-DRB1 variants linked with high viremia ( Fig. 3a , P = 0.018, Fisher's exact test). In particular, HLA-DRB1 variants linked with low viremia were able to promiscuously present a total of 21 Gag peptides, yet only 14 Gag peptides were restricted by HLA-DRB1 variants linked with high viremia. Moreover, Nef peptides were exclusively restricted by HLA-DRB1 variants linked with low viremia. A caveat to this approach is that odds ratio values can only be used as an approximate guide for stratifying alleles into the two groupings, given that many alleles had wide confidence intervals in the precision of their odds ratio estimates, and only two individual alleles (HLA-DRB1*15:01 and HLA-DRB1*03:01) were significantly associated with HIV control after correction for multiple comparisons. Nevertheless, the observed functional comparisons remained significant even after higher-stringency selection of HLA-DRB1 alleles on the basis of 10% significance before multiple comparisons (P = 0.0148) ( Supplementary Table 5 ).
We next investigated whether subjects with HLA-DRB1 alleles linked to lower viremia have generally broader HIV-specific CD4 + T cell responses when compared to subjects that express HLA-DRB1 alleles linked with higher viremia. For this analysis, we evaluated the breadth of HIV-specific CD4 + T cell responses in a subcohort of 43 treatment-naive, chronically HIV-infected subjects, with the exception of subjects with HLA-DRB1*15:02, for whom sample npg availability limited us to Gag, Nef and Env gp120 only (which probably underestimates the total breadth). We detected no significant differences between the two groups in their mean HIV viral load or CD4 + T cell count (Supplementary Fig. 3) . Notably, individuals with HLA-DRB1 alleles linked with low viremia showed significantly greater breadth of overall HIV-specific CD4 + T cell responses directly ex vivo than individuals with HLA-DRB1 alleles linked with higher viremia (Fig. 3b , P = 0.0395, Mann-Whitney U-test). The wide variability in HIV-specific CD4 + T cell responses within each group exists because each individual expresses a variety of HLA class II alleles, and thus some peptide-specific responses within the total breadth are probably restricted by an allele that is neither protective nor non-protective. We also assessed the functional binding avidity of peptide-specific CD4 + T cell lines restricted in the context of HLA-DRB1 variants linked with lower as compared with higher viremia. Unexpectedly, we observed that CD4 + T cells specific for HLA-DRB1 variants linked with low viremia in general bind HIV epitopes with lower functional avidity compared to CD4 + T cells specific for those variants linked with high viremia (Fig. 3c , P < 0.05, two-way analysis of variance (ANOVA) with Bonferroni correction). These data suggest a hypothesis in which HLA-DRB1 variants linked with low viremia may bind at lower avidity and may show greater promiscuity in their peptide interactions as compared to those associated with high viremia. This difference in binding modality might give HIV-specific CD4 + T cell responses restricted by potentially protective HLA-DRB1 variants a survival advantage, in which CD4 + T cells with lower binding avidity are less activated and thus less susceptible to infection or activation-induced cell death 19, 20 . The contribution of HLA class II peptide presentation to the control of viral infection in humans has been poorly defined. Here, we provide, to our knowledge, the first systematic approach to the analysis of HIV-specific CD4 + T cell peptides restricted by HLA-DRB1 variants linked with high or low odds ratios. Peptide restrictions were grouped according to protein (Gag, Nef, Env, Pol and Acc (Accessory)). P = 0.018, Fisher's exact test, 33/93 low odds ratio, 22/108 high odds ratio. (b) Breadth of total HIV-specific CD4 + T cell responses in HIV-infected individuals expressing HLA-DRB1 variants linked with high or low odds ratios (P = 0.0395, Mann-Whitney U-test). Subjects expressing HLA-DRB1 alleles linked with a low odds ratio are depicted by circles (n = 15), subjects expressing HLA-DRB1 alleles linked with a high odds ratio are depicted by squares (n = 28) and subjects expressing HLA-DRB1*15:02 tested only for Gag, Nef and Env gp120 peptides are depicted by triangles (n = 3). Median is depicted with interquartile range. Individuals expressing more than one protective or nonprotective allele were only counted once, and none of the subjects dually expressed both alleles. (c) Functional avidity of CD4 + T cell lines restricted by HLA-DRB1 variants linked with high or low odds ratios. Significant P values are denoted by an asterisk (*) (P > 0.05, two-way ANOVA after Bonferroni correction). Subjects expressing low odds ratio-linked HLA-DRB1 alleles are depicted by circles (n = 9), and subjects expressing high odds ratio-linked HLA-DRB1 alleles are depicted by squares (n = 8). Data are expressed as means ± s.e.m. Interferon-γ (IFN-γ) spot-forming units at 20 µM were normalized to 100%. npg HLA-DRB1 restrictions and show that HLA-DRB1 allele diversity may affect immune containment of HIV infection at the population level. In particular, the alleles HLA-DRB1*15:02 and HLA-DRB1*03:01 were significantly associated with HIV control and progression, respectively, and this association remained significant even after correction for multiple comparisons. The strength of these HLA-DRB1mediated effects was independent of HLA-B*57, HLA-B*27 and HLA-B*35Px, yet it was markedly less than has been observed for these and other HLA class I alleles 9, 10 . Notably, the HLA class II alleles HLA-DRB1*03:01 and HLA-DRB1*15:02 were also listed among the many HLA class I alleles implicated in influencing viral control in a genome-wide association study analysis, yet only HLA-B*57 was independently associated with a protective effect 10 . In sum, these data provide, to our knowledge, the first evidence linking HLA class II genetic associations with the functional responses of CD4 + T cells and point to an important role for HIV-specific CD4 + T cells in the control of HIV infection.
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